The 2nd International Joint Symposium of JSBMS and MSACL
(Date: September 9th, 2022)
◆ Organizers
・Kazuo Igarashi, Ph.D.
Executive Head, Association of Medicinal Analysis.
・Kenji Nakayama, Ph.D.
Associate Professor, Department of Clinical Engineering and Medical Technology, Faculty of Medical Technology, Niigata University of Health and Welfare.
◆ Keynote Speakers
1) Masaya Ikegawa, MD, Ph.D. (from JSBMS)
Professor, Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha University.
“Mass spectrometry imaging in Alzheimer’s disease”
[Short Bio]
Masaya Ikegawa graduated from Faculty of Medicine and Graduate School of Medicine Kyoto University and obtained MD and phD. He started his omics studies at Professor Tasuku Honjo’s laboratory at Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University. Now he is a professor at Department of Medical Life Systems, Doshisha University in Kyoto and leading the laboratory for Genomics and Proteomics for Human and Model Organisms. His laboratory is working on developing a strategy of mass spectrometry based in situ proteomic and metabolomics. Through clinical and pathological knowledges as well as bioinformatics, the current strategy will open a novel avenue to understand, diagnose and cure intractable diseases, such as Alzheimer’s Disease (AD).
2) Kenji Nakayama, Ph.D. (from JSBMS)
Associate Professor, Department of Clinical Engineering and Medical Technology, Faculty of Medical Technology, Niigata University of Health and Welfare.
“qShot MALDI phospholipidomics and its Clinical Applications”
[Short Bio]
Dr. Kenji Nakayama learned his mass spectrometric knowledge and techniques at University Medical Center Groningen in 2008. His mass spectrometric career started with a surface-enhanced laser desorption/ionization (SELDI) -TOF/MS analysis. At that time, that wonderful mass spectrometric technique impressed him, prospecting the applications of neonatal screening tests as well as early diagnosis examinations of many diseases. At present, he has focused on the quantitative analysis using MALDI-TOF/MS and tried to improve the quantitative precision of this method.
3) Andy Hoofnagle, MD, Ph.D. (from MSACL)
Professor, Division of Clinical Chemistry, Department of Laboratory Medicine and Pathology, University of Washington.
“Measuring Proteins by LC-MS/MS: Improving Clinical Research and Patient Care”
[Short Bio]
Dr. Hoofnagle's laboratory focuses on the precise quantification of recognized protein biomarkers in human plasma using LC-MRM/MS. In addition, they have worked to develop novel assays for the quantification of small molecules in clinical and research settings. His laboratory also studies the role that the systemic inflammation plays in the pathophysiology of obesity, diabetes, and cardiovascular disease.
4) Daniel Holmes, MD, Ph.D. (from MSACL)
Professor, Department of Pathology and Laboratory Medicine, University of British Columbia.
“IgG4 Related Disease Diagnosis and Monitoring using LC-MS/MS: Advantages over Nephelometry”
[Short Bio]
Daniel Holmes earned his undergraduate degree in Chemical Physics from the University of Toronto. He went to medical school at the University of British Columbia (UBC) where he also did his residency in Medical Biochemistry. He is a Clinical Professor of Pathology and Laboratory Medicine at UBC and Head and Medical Director of the Department of Pathology and Laboratory Medicine at St. Paul’s Hospital in Vancouver. Interests include clinical endocrinology with a focus on secondary hypertension, lipidology, clinical mass spectrometry, and data science in application to data automation, visualization and clinical utilization.